Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 12/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.39 |
| ▸ | ATR | Q13535 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29019241 | 0.87 | MEN1 (0.50) | LCKCA1CA2PI4KBNPSR1 | |
| SCHEMBL23413609 | 0.86 | CA1 (0.44) | LCKCA1CA2PI4KBATR | |
| SCHEMBL19801577 | 0.84 | LCK (0.46) | LCKCA1CA2PI4KB | |
| SCHEMBL15348877 | 0.84 | NPC1 (0.47) | LCKCA1CA2PI4KB | |
| SCHEMBL23214462 | 0.83 | LCK (0.46) | LCKCA1CA2PI4KBATR | |
| SCHEMBL28733811 | 0.83 | CA1 (0.44) | LCKCA1CA2PI4KBATR | |
| SCHEMBL150084 | 0.81 | LCK (0.58) | LCKCA1CA2PI4KB | |
| SCHEMBL2952498 | 0.81 | CA1 (0.42) | LCKCA1CA2PI4KBATR | |
| SCHEMBL24434747 | 0.81 | L3MBTL1 (0.47) | LCKCA1CA2PI4KBATR | |
| SCHEMBL31214147 | 0.81 | CA1 (0.42) | LCKCA1CA2PI4KBATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3512602-B1 | INHIBITORS OF HEAT SHOCK FACTORS (HSF) AND USES THEREOF | HSF PHARMACEUTICALS (CH) | 2024-03-27 | — | — | EP | disclosed |
| CN-117279896-A | Amino substituted pyrido ring compounds, preparation method and application thereof | 劲方医药科技(上海)有限公司 | 2023-12-22 | — | — | CN | disclosed |
| US-11597708-B2 | Inhibitors of heat shock factors and uses thereof | HSF PHARMACEUTICALS SA (CH) | 2023-03-07 | — | — | US | disclosed |
| WO-2022214044-A1 | AMINE-SUBSTITUTED PYRIDINE FUSED RING COMPOUNDS, PREPARATION METHOD THEREFOR AND USE THEREOF | 劲方医药科技(上海)有限公司 | 2022-10-13 | — | — | WO | disclosed |
| US-20210221778-A1 | Inhibitors of heat shock factors and uses thereof | HSF PHARMACEUTICALS SA (CH) | 2021-07-22 | — | — | US | disclosed |
| EP-3512602-A2 | INHIBITORS OF HEAT SHOCK FACTORS AND USES THEREOF | HSF Pharmaceuticals (CH) | 2019-07-24 | — | — | EP | disclosed |
| WO-2018050656-A2 | INHIBITORS OF HEAT SHOCK FACTORS AND USES THEREOF | HSF PHARMACEUTICALS (CH) | 2018-03-22 | — | — | WO | disclosed |
| WO-2018050656-A2 | INHIBITORS OF HEAT SHOCK FACTORS AND USES THEREOF | HSF PHARMACEUTICALS (CH) | 2018-03-22 | — | — | WO | disclosed |
| EP-1981884-B1 | THIAZOLE COMPOUNDS AS PROTEIN KINASE B (PKB) INHIBITORS | AMGEN INC (US) | 2012-06-13 | — | — | EP | disclosed |
| US-8084479-B2 | Thiazole compounds and methods of use | AMGEN INC. (US) | 2011-12-27 | — | — | US | disclosed |
| EP-2387570-A1 | FLUOROISOQUINOLINE SUBSTITUTED THIAZOLE COMPOUNDS AND METHODS OF USE | Amgen, Inc (US) | 2011-11-23 | — | — | EP | disclosed |
| US-20110263647-A1 | FLUOROISOQUINOLINE SUBSTITUTED THIAZOLE COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2011-10-27 | — | — | US | disclosed |
| WO-2010083246-A1 | FLUOROISOQUINOLINE SUBSTITUTED THIAZOLE COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2010-07-22 | — | — | WO | disclosed |
| US-20090270445-A1 | Thiazole compounds and methods of use | AMGEN INC. (US) | 2009-10-29 | — | — | US | disclosed |
| US-20090270445-A1 | Thiazole compounds and methods of use | AMGEN INC. (US) | 2009-10-29 | — | — | US | disclosed |
| US-7514566-B2 | Thiazole compounds and methods of use | AMGEN, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-7514566-B2 | Thiazole compounds and methods of use | AMGEN, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| WO-2007084391-A2 | THIAZOLE COMPOUNDS AS PROTEIN KINASE B ( PKB) INHIBITORS | AMGEN INC. (US) | 2007-07-26 | — | — | WO | disclosed |
| US-20070173506-A1 | Thiazole compounds and methods of use | AMGEN INC. (US) | 2007-07-26 | — | — | US | disclosed |
| US-20070173506-A1 | Thiazole compounds and methods of use | AMGEN INC. (US) | 2007-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11597708-B2 | Inhibitors of heat shock factors and uses thereof | HSF1, HSP90AB2P, HSP90AB1 | LCK 2256/4885CA1 3312/4885CA2 3149/4885 |
| US-20110263647-A1 | FLUOROISOQUINOLINE SUBSTITUTED THIAZOLE COMPOUNDS AND METHODS OF USE | TFEB, PCK2, JAK2 | LCK 253/4885CA1 3816/4885CA2 1505/4885 |
| US-20210221778-A1 | Inhibitors of heat shock factors and uses thereof | HSF1, HSP90AB2P, HSP90AB1 | LCK 2256/4885CA1 3312/4885CA2 3149/4885 |
| US-20090270445-A1 | Thiazole compounds and methods of use | MTOR, JAK2, TK2 | LCK 313/4885CA1 3657/4885CA2 1110/4885 |
| US-20070173506-A1 | Thiazole compounds and methods of use | MTOR, JAK2, PCK2 | LCK 473/4885CA1 3346/4885CA2 904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.